J&J reports strong Darzalex sales, discontinues antibiotic

Johnson & Johnson (NYSE:JNJ) reported 1Q18 earnings, including stronger-than-expected sales of Darzalex daratumumab, and raised its full-year sales guidance.

The company now expects 2018 sales of $81.0-$81.9 billion, up from $80.6-$81.4 billion. Sales of Darzalex were $432 million worldwide during 1Q18, topping analysts' consensus of $396 million...